Search

Your search keyword '"Chernov, V. I."' showing total 227 results
Start Over Author "Chernov, V. I."
227 results on '"Chernov, V. I."'

5. Diagnosis of sentinel lymph nodes in patients with cancer of the larynx and laryngopharynx using a new radiopharmaceutical based on technetium-99m-labeled gamma aluminum oxide

Author

Medvedeva, A. A., primary, Chernov, V. I., additional, Bragina, O. D., additional, Zeltchan, R. V., additional, Choynzonov, E. L., additional, Chizhevskaya, S. Yu., additional, Rуbina, A. N., additional, Gol’dberg, A. V., additional, and Сheremisina, O. V., additional

Published
2023
Full Text
View/download PDF

6. A direct comparison of the diagnostic efficacy of alternative scaffold- based radiopharmaceuticals [99mTc]Tc-ADAPT6 and [99mTc]Tc-(HE)3-G3 in patients with HER2-positive breast cancer

Author

Bragina, O. D., Deyev, S. M., Garbukov, E. Yu, Goldberg, V. E., Chernov, V. I., Tolmachev, Vladimir, Bragina, O. D., Deyev, S. M., Garbukov, E. Yu, Goldberg, V. E., Chernov, V. I., and Tolmachev, Vladimir

Abstract

Aim. To perform a direct comparison of the diagnostic efficacy of [(99)mTc]Tc-ADAPT6 and [(99)mTc]Tc-(HE)3-G3 in HER2-positive breast cancer patients before the systemic treatment.Materials and methods. The study included 11 patients with HER2-positive breast cancer (T1-4N0-2M0-1) before the initiation of systemic treatment. All patients underwent a radionuclide examination with [(99)mTc]Tc-ADAPT6 and [(99)mTc]Tc-(HE)3-G3 with the interval of 3-4 days. Single-photon emission computed tomography (SPECT) /computed tomography (CT) was performed 2 and 4 hours after [(99)mTc]Tc-ADAPT6 and [(99)mTc]Tc-(HE)3-G3 administration, respectively.Results. The analysis of [(99)mTc]Tc-ADAPT6 and [(99)mTc]Tc-(HE)3-G3 distribution showed their high uptake in the kidneys and liver. Breast tumors were visualized in all cases. The average tumor uptake of [(99)mTc]Tc-ADAPT6 was 4.7 +/- 2.1, which was significantly higher than in the [(99)mTc]Tc-(HE)3-G3 injection (3.5 +/- 1.7) (p < 0.005, paired t-test). The tumor-to-background ratio (15.2 +/- 7.4 and 19.6 +/- 12.4, respectively) had no statistical differences in both cases (p > 0.05, paired t -test). Liver metastases were visualized in patients 1 and 5 and corresponded to the projection of metastases according to contrast-enhanced abdominal CT. The accumulation of [(99)mTc]Tc-ADAPT6 and [(99)mTc]Tc-(HE)3-G3 in the projection of metastases in both cases was significantly higher compared to the primary tumor (1.3 and 1.7 times higher in patient 1; 2.2 and 3.5 times higher in patient 5, respectively).Conclusion. Both [(99)mTc]Tc-ADAPT6 and [(99)mTc]Tc-(HE)3-G3 demonstrated the diagnostic efficacy in visualizing a primary HER2-positive tumor in breast cancer patients. However, [(99)mTc]Tc-ADEPT6 had higher accumulation values, which makes it a more promising diagnostic agent.

Published
2023
Full Text
View/download PDF

8. Current status of nuclear cardiology in the Russian Federation

Author

ZavadovskyZavadovsky, K. V., primary, Vesnina, Zh. V., additional, Anashbaev, Zh. Zh., additional, Mochula, A. V., additional, Sazonova, S. I., additional, Ilyushenkova, Yu. N., additional, Shipulin, V. V., additional, Varlamova, Yu. V., additional, Ansheles, A. A., additional, Aslanidi, I. P., additional, Valiullina, N. M., additional, Vakhromeeva, M. N., additional, Volodina, V. V., additional, Davydov, G. A., additional, Drizner, E. A., additional, Znamensky, I. A., additional, Karpov, E. N., additional, Kokov, A. N., additional, Kudryashova, N. E., additional, Minin, S. M., additional, Mirzoyants, S. G., additional, Ryzhkova, D. V., additional, Sadchikov, A. A., additional, Sayfullina, G. B., additional, Sergienko, V. B., additional, Smolyarchuk, M. Ya., additional, Starikova, E. V., additional, Sukhov, V. Yu., additional, Talantov, S. V., additional, Tempel, M. V., additional, Teffenberg, D. V., additional, Tomashevsky, I. O., additional, Trifonova, T. A., additional, Udodov, V. D., additional, Chernov, V. I., additional, and Shurupova, I. V., additional

Published
2023
Full Text
View/download PDF

15. Clinical possibilities of HER2-positive breast cancer diagnosis using alternative scaffold proteins

Author

Bragina, O. D., Chernov, V. , I, Deyev, S. M., Tolmachev, Vladimir, Bragina, O. D., Chernov, V. , I, Deyev, S. M., and Tolmachev, Vladimir

Abstract

HER2-positive breast cancer occurs in 15-20% of breast cancer patients and is associated primarily with a poor prognosis of the disease and the need for highly specific targeted therapy. Despite the clinical importance of determining HER2/neu, traditional diagnostic methods have their disadvantages and require the study of new additional research techniques. The information presented in this review makes it possible to consider current trends in the radionuclide diagnosis of HER2-positive breast cancer using the latest class of alternative scaffold proteins and to consider various aspects of their use in clinical practice.

Published
2022
Full Text
View/download PDF

29. Possibilities of radionuclide diagnostics of Her2-positive breast cancer using technetium-99m-labeled target molecules : the first experience of clinical use

Author

Bragina, O. D., Chernov, V. I., Garbukov, E. Yu, Doroshenko, A. V., Vorobyeva, Anzhelika, Orlova, Anna, Tolmachev, Vladimir, Bragina, O. D., Chernov, V. I., Garbukov, E. Yu, Doroshenko, A. V., Vorobyeva, Anzhelika, Orlova, Anna, and Tolmachev, Vladimir

Abstract

Background. The main purpose of the Her2/neu status determination in clinical practice is to determine the indications for the appointment of targeted therapy. The main methods for detecting the Her2/neu status are the immunohistochemical method (IHC) and the fluorescence in situ hybridization (FISH); however, despite their widespread use, they have a number of significant disadvantages. Over the past few years, radionuclide diagnostics using a new class of alternative scaffold proteins that meet all the requirements for optimal delivery of radionuclides to tumor cells has become widespread. Aim. To study the possibility of clinical use of a radiopharmaceutical based on technetium-99m-labeled target molecules for the diagnosis of breast cancer with the Her2/neu overexpression in humans. Materials and methods. The study included 11 patients with breast cancer (T1–4N0–2M0) before systemic therapy: 5 with Her2/neu overexpression; expression of the marker was not detected in 6. In all cases, morphologicaland immunohistochemical studies were performed. In case of Her2/neu 2+, FISH analysis was performed. The radiopharmaceutical was prepared immediately before administration, after which it was slowly injected intravenously into the patient. Scintigraphic studies in the “WholeBody” mode and SPECT of the chest organs were performed 2, 4, 6 and 24 hours after injection. Results. Radiochemical yield, radiochemical purity and activity before administration were (80 ± 4)%, (98 ± 1)% and (434 ± 19.5) MBq, respectively. The greatest uptake by normal organs was observed at a time interval of 6 hours in the kidneys and at a moderate activity in the liver and lungs at the same time interval. The organ with the highest absorbed dose was the kidneys; significant accumulation was also detected in the adrenal glands, gallbladder, liver, pancreas and spleen. The smallest accu mulation of the studied drug was observed in the brain (0.001 ± 0.000) mGy and skin (0.001 ± 0.000) mGy. Th

Published
2021
Full Text
View/download PDF

36. METABOLIC SINGLE-PHOTON EMISSION COMPUTED TOMOGRAPHY WITH THE NEW RADIOPHARMACEUTICAL ⁹⁹ᵐTc-1-thio-D-glucose IN THE DIAGNOSIS AND MONITORING OF THE PRIMARY BREAST LYMPHOMA (CASE REPORT)

Author

Dudnikova, Ye. A., primary, Chernov, V. I., additional, Muravleva, A. V., additional, Kravchuk, T. L., additional, Zelchan, R. V., additional, Medvedeva, A. A., additional, Bragina, O. D., additional, Simolina, Ye. L., additional, Popova, N. O., additional, Vysockaja, V. V., additional, Lukina, N. M., additional, Shatalova, V. A., additional, Shpileva, O. V., additional, Goldberg, A. V., additional, and Goldberg, V. Ye., additional

Published
2020
Full Text
View/download PDF

42. Development of a method for preparing octreotide derivative for diagnosis of neuroendocrine tumors

Author

Larkina, M. S., primary, Podrezova, E. V., additional, Bragina, O. D., additional, Tagirova, E. A., additional, Chernov, V. I., additional, Yusubov, M. S., additional, Nesterov, E. A., additional, Skuridin, V. S., additional, Krivoshchekov, S. V., additional, Yanovskaya, E. A., additional, Gurto, R. V., additional, and Belousov, M. V., additional

Published
2019
Full Text
View/download PDF

44. THE VALUE OF PET/CT IN THE DIAGNOSIS, STADING AND MONITORING OF COLORECTAL CANCER

Author

Chernov, V. I., primary, Goncharova, N. M., additional, Goldberg, V. E., additional, Dudnikova, E. A., additional, Zelchan, R. V., additional, Medvedeva, A. A., additional, Sinilkin, I. G., additional, Bragina, O. D., additional, Avgustinovich, A. V., additional, Goldberg, A. V., additional, Ermolenko, R. V., additional, Popova, N. O., additional, Simolina, E. I., additional, and Vysotskaya, V. V., additional

Published
2019
Full Text
View/download PDF

47. Validation of an Analytical HPLC Method for a New Diagnostic Octreotide Derivative for Neuroendocrine Tumors.

Author

Lar'kina, M. S., Krivoshchekov, S. V., Podrezova, E. V., Bragina, O. D., Chernov, V. I., Nesterov, E. A., Bodenko, V. V., Belousov, M. V., and Yusubov, M. S.

Subjects
NEUROENDOCRINE tumors, QUALITY control, DETECTION limit, MANUFACTURED products, QUALITY assurance
Abstract

Preclinical studies of a new octreotide derivative with a chelate (DPAH-octreotide) that binds 99mTc for radiological diagnosis of neuroendocrine tumors are currently in progress. A method for preparing DPAH-octreotide is based on forming an amide bond between the amine of D-phenylalanine and the bifunctional chelate succinimid-1-yl 6-[bis(pyridin-2-ylmethyl)amino]hexanoate. An HPLC method for determining the identity, impurities, and quantitative content is proposed for DPAH-octreotide quality assurance. The validation protocol established that the HPLC analytical method for determining DPAH-octreotide had quality parameters for specificity, detection limit, linearity, accuracy, precision, and intralaboratory precision that met requirements for analytical methods and could be used for quality control of the finished product during manufacturing of reagents for preparation of related radiopharmaceuticals. [ABSTRACT FROM AUTHOR]

Published
2019
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results